Lupin Limited has entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited to co-market Zydus’ innovative Semaglutide Injection (15 mg/3 ml) in India, effective March 17, 2026. Lupin will market the drug under the brand names Semanext and Livarise, focusing on expanding patient access to advanced therapies for Type 2 diabetes and weight management across India. Zydus will retain marketing rights under its existing brands.
Lupin Secures Semi-Exclusive Marketing Rights for Semaglutide Injection
Global pharmaceutical major Lupin Limited announced on March 17, 2026, that it has signed a Licensing and Supply Agreement with Zydus Lifesciences Limited. This strategic partnership is focused on expanding patient access to an innovative Semaglutide Injection (15 mg/3 ml) delivered via a patient-friendly reusable pen device across India.
Under the terms of the agreement, Lupin has been granted semi-exclusive rights to co-market Zydus’ Semaglutide Injection. Lupin will launch the product under two distinct brand names: Semanext and Lupin’s Livarise. Concurrently, Zydus will continue marketing the same product under its existing brands: SEMAGLYN™, MASHEMA™, and ALTERME™. The collaboration aims to leverage Lupin’s extensive market reach with Zydus’ robust development capabilities.
Financial Terms and Strategic Focus
As part of the commercial arrangement, Lupin will provide Zydus with upfront licensing fees along with potential milestone payments upon the achievement of pre-defined success criteria. This alliance reinforces Lupin’s commitment to advancing treatment options for cardio-metabolic diseases, particularly as GLP-1 therapies continue to redefine global standards.
Nilesh Gupta, Managing Director, Lupin, emphasized that the partnership strengthens their diabetes portfolio and addresses unmet patient needs in the cardio-metabolic space. Similarly, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., highlighted that joining hands with Lupin will significantly broaden access to the medicine and its novel delivery device across India.
Product Indication Overview
The Semaglutide injection is indicated for several clinical applications:
- Treatment of adults with insufficiently controlled Type 2 diabetes mellitus, used as an adjunct to diet and exercise.
- As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
- In addition to other medicinal products for diabetes treatment.
- As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults meeting specific BMI criteria (obesity or overweight) alongside at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia).
Source: BSE
